Breast Cancer

P2, N=40, Completed, Beijing Wehand-Bio Pharmaceutical Co., Ltd | Phase classification: P1 --> P2

P=N/A, N=60, Completed, University of Washington | Active, not recruiting --> Completed

P2, N=702, Recruiting, West German Study Group | Active, not recruiting --> Recruiting | N=402 --> 702 | Trial completion date: Jun 2029 --> Sep 2030 | Trial primary completion date: Jun 2025 --> Jun 2030

P2, N=606, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

P=N/A, N=100, Not yet recruiting, Weill Medical College of Cornell University

P=N/A, N=68, Active, not recruiting, Mayo Clinic | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2028

This case represents a rare report of surgical resection for breast cancer liver metastasis after CDK4/6 inhibitor-based therapy. It suggests that local treatment may be effective even in cases with suspected endocrine-resistant disease and provides practical insight into patient selection and treatment strategies, as the case fulfilled previously reported criteria for local therapy.

However, whole-body ⁶⁸Ga-FAPI PET/CT revealed a markedly different disease burden. This case highlights the added diagnostic value of ⁶⁸Ga-FAPI PET/CT in detecting the true extent of ILC, particularly when conventional imaging appears limited.

The TGFβRI inhibitor LY2157299 attenuates fibrosis in vivo. Strikingly, PT637 disrupts the Spata13-TGFβRI interaction and reduces both fibrosis markers and capsular thickness in biofilm-challenged rats. We define Spata13 as a novel regulator of infection-associated fibrosis and demonstrate that targeted disruption of Spata13-TGFβRI binding by PT637 offers a precision therapeutic strategy for capsular contracture.

LN metastasis is associated with a remodelled systemic immunity, enriches immunosuppressive neutrophils and TandNK cells and activates LGALS9‒HAVCR2 signalling. These findings reveal immune signatures associated with LN metastasis status and identify candidate biomarkers and therapeutic targets warranting further validation.

In this nationwide propensity score-matched cohort, adjuvant Lipo-Dox was associated with sustained overall survival benefits without increased cardiotoxic risk compared with epirubicin. Lipo-Dox may represent a favorable anthracycline alternative, particularly for patients with cardiovascular comorbidities or elevated cardiotoxicity risk.

We consider ET suitability to be the clinical assessment of whether a patient could benefit from ET, where benefit is defined not solely by tumor response but by a clinically relevant constellation of characteristics and markers possibly predicting the durability of disease response and symptom control. Several unresolved questions remain regarding issues such as disease heterogeneity, optimal treatment sequencing, and biomarker precision, but further work and ongoing studies will help to support the evolution of guidelines and provide clarity around the effective application of this quickly developing field to daily clinical practice.